Via Xinhua: Guangdong's first H7N9 patient discharged. Excerpt from an edited Google translation:
Concern about a week, Guangdong's first H7N9 patient can be discharged! Yesterday, the reporter was informed at a briefing on Guangdong's first H7N9 patient that the first case of H7N9 in Guangdong provinces that Ms. Chen has improved markedly after more than 20 days of full treatment and intensive care in Guangzhou Medical Institute. She is now in a general ward.
Patient: Fully recovered after one month
At yesterday's briefing, Academician Zhong Nanshan said the Institute had transferred the patient,. Her lung function had been poor, and the oxygen index was very low, accompanied by heart failure and blood problems But after 20 days of treatment, cardiac function has significantly improved and she has also had some time to recover.
According to the director of the Institute, Chen Rongchang, given her present condition the patient should be discharged in about a week. Her health will be restored, with basically no sequelae.
Yesterday, the reporter saw Ms. Chen in the general ward where she has been transferred. I saw her color is very good, with a smile on her face. She told reporters that she had a good recovery. Eating and sleeping are normal, she feels basically no discomfort, but still can not move around too much too soon.
Epidemic: Winter and spring vigilance
Is Ms. Chen the only case of H7N9 in Guangdong? Zhong Nanshan said occurrence and identification are two different concepts. "I can only say that, so far, we have found only in this case in Guangdong. Because there is no census, maybe some cases might be just mild infections that have not been found. So we're now unable to make accurate morbidity and mortality statistics."
Will Guangdong see more H7N9 cases this winter and spring?
Zhong Nanshan said that at present he can only say that there is a possibility, but no one dares to conclude that will happen. Now there's evidence: First, there are already limited human-to-human transmission; second, in animal experiments, there is a certain possibility of droplet infection. "Of course, this is just animal experiments, human experiments have not been confirmed, so this winter and spring are still worthy of attention."This extensive report goes on to say that the cost of treating Ms. Chen as of September 2 is 218,977 yuan (US$35,785). While her medical insurance will cover much of this, she will still have to pay 42,930 yuan—US$7,015. Given what she's taught the Chinese medical establishment, the government ought to be paying her at least that much.